How to choose a continuous glucose monitor: Dexcom G7 vs FreeStyle Libre 3 vs Eversense 365

Not all CGMs are the same. We break down the three systems we prescribe most — Dexcom G7, FreeStyle Libre 3, and Eversense 365 — so you can have an informed conversation with us about which one fits your life.

By Rakesh Patel, DO · Last reviewed 2026-05-25

A continuous glucose monitor — a CGM — is one of the most powerful tools we have for managing diabetes. Instead of a snapshot from a fingerstick, a CGM gives you a rolling picture: a glucose reading every few minutes, day and night, with trends, alarms, and weeks of data that we can review together. For patients on insulin especially, CGM changes the game. For many others, even a few months of CGM data teaches you things about your own glucose that no A1C ever could.

We currently prescribe three systems. Each one is excellent. Each one is also meaningfully different. Here is how we think about the choice.

The three systems we prescribe most

Dexcom G7

The G7 is a small sensor you wear on your upper arm. It lasts 10 days per sensor, requires no fingerstick calibration, and pairs with an app on your smartphone or the dedicated Dexcom receiver. It streams glucose values every five minutes and can share readings in real time with caregivers or partners. The alarms are highly customizable — you can set a high threshold, a low threshold, an urgent-low alert, and a rate-of-change alarm so you know when your glucose is falling fast even before it hits a dangerous level.

The G7 also integrates with the Tandem t:slim X2 insulin pump for automated insulin delivery — meaning the pump reads the CGM and adjusts your basal rate automatically. If you are on or considering a pump, the G7 is currently the most mature integration option we use.

FreeStyle Libre 3

The Libre 3 is Abbott's current-generation sensor — notably smaller than the G7, also worn on the upper arm, and lasting 14 days per sensor. Like the G7, it requires no calibration and streams continuously to an app. Abbott has also added real-time alarms in the Libre 3, which were absent in earlier Libre generations.

The Libre 3 tends to cost less out of pocket and has broad insurance coverage, including Medicare. If cost is a significant factor and you do not need pump integration, the Libre 3 is often the right starting point. It is also a good fit for patients who want the smallest possible sensor profile.

Eversense 365

The Eversense 365 is in a different category entirely. Instead of a patch that sits on your skin for 10-14 days, the Eversense sensor is a small implant — about the size of a small vitamin — placed just under the skin of your upper arm in a brief in-office procedure. It lasts a full year. You wear a removable transmitter on top of the skin over the implant site; the transmitter is rechargeable and sends glucose data to your phone. There is no adhesive patch at all.

EPC is one of a very small number of practices in the Houston area that places and removes Eversense sensors in-office. The procedure takes about 10-15 minutes in each direction. For patients who have struggled with skin reactions, adhesive fatigue, or sensor adhesion failures — and for patients whose lifestyle makes a year without a weekly patch change appealing — this is a genuinely different option, not just a marketing alternative.

How to choose between them

Cost and insurance coverage

All three systems have Medicare coverage. Private insurance coverage is broad but varies. In general, the Libre 3 tends to have the lowest out-of-pocket cost, the G7 is in the middle, and Eversense 365 has higher upfront costs (the insertion procedure plus the sensor) but potentially lower per-day cost over a year compared to 10-day sensors. We handle prior authorization for all three systems — you do not need to navigate that yourself. We will tell you what your specific plan covers before you commit.

Skin reactions and adhesive fatigue

This is more common than people realize. Wearing an adhesive patch on your arm continuously for weeks, months, and years can lead to contact dermatitis, skin breakdown, or just plain frustration. Both the G7 and Libre 3 have adhesive patches, and there are over-patches and barrier products that help. But if adhesive tolerance is a real problem for you, Eversense solves it at the root — there is no sticky patch involved in glucose sensing at all, only the removable transmitter.

Sport and lifestyle

For competitive swimmers, triathletes, wrestlers, or anyone in frequent contact sports, keeping a sensor patch adhered for 10-14 days in a row can be a constant battle. Eversense wins here clearly — the implant is not going anywhere, and the transmitter can be removed and replaced without affecting glucose tracking. If you exercise heavily and have had sensor-adhesion failures, this is a real reason to consider the implant option.

For patients who are needle-averse or anxious about device insertion, the Libre 3's smaller inserter profile feels less intimidating. Eversense requires a minor in-office procedure, which is not the right choice for everyone — we talk through it honestly.

Pump integration

If you are on a Tandem t:slim X2 pump, the Dexcom G7 is your CGM — that integration drives the Control-IQ automated insulin delivery algorithm. Omnipod 5 also pairs with the G7. Medtronic's 780G system uses its own Guardian 4 sensor. If you are on or planning a pump, the CGM choice is often dictated by the pump. We will walk through this together.

Alarm preferences

Some patients want to hear every out-of-range reading. Others find constant alarms eroding their quality of life — alarm fatigue is real. All three systems allow alarm customization. The Dexcom G7 has the most granular alarm settings and the loudest urgent-low alarm. If you live alone, are a deep sleeper, or have hypoglycemia unawareness, robust alarms matter a great deal.

Sensor visibility

The Libre 3 has the smallest sensor profile and is the least visible under clothing. The G7 is slightly larger. The Eversense transmitter is worn on top of the skin and is visible as a small oval — but it can be removed at any time for events where you would prefer not to wear it.

Who CGM is for

CGM is standard of care for everyone with Type 1 diabetes. For Type 2, the answer has expanded substantially. Medicare now covers CGM for Type 2 patients who are on any insulin — basal only, basal-bolus, or pump — and coverage is expanding for patients on GLP-1 medications even without insulin.

Beyond insulin-requiring diabetes, we also use CGM for:

  • Gestational diabetes, where glucose targets are tighter and fingersticks alone often miss important patterns
  • Hypoglycemia unawareness — patients who have lost the early warning symptoms of low glucose and need an alarm to catch drops they can no longer feel
  • Brittle or highly variable glucose in patients who have been difficult to stabilize on traditional monitoring
  • Short-term use in prediabetes — often self-pay — to see how diet, exercise, stress, and sleep affect glucose in real time; even a few weeks of data at the prediabetes stage can be instructive and motivating

CGM may not be the right fit for patients who find continuous data anxiety-provoking rather than empowering. That is worth talking about honestly. Technology should serve the patient, not the other way around.

What CGM data actually looks like

Your CGM app shows a live glucose curve. But when we sit down together at your visit, we look at something called the Ambulatory Glucose Profile — the AGP — which compresses weeks of data into a single standardized chart. We focus on four things:

  • Time in Range (TIR): the percentage of time your glucose was between 70 and 180 mg/dL. For most patients on insulin, the target is 70% or higher. For pregnancy, targets are tighter: 63-140 mg/dL.
  • Time below range: percentage of time below 70 mg/dL (low) and below 54 mg/dL (very low). We want this as close to zero as possible. Even 1% below 54 mg/dL equals about 15 minutes per day in the danger zone — which matters.
  • Glucose Management Indicator (GMI): an estimated A1C derived from your CGM average. It is a useful check, but your lab A1C and GMI will sometimes differ, especially if you have a hemoglobin variant or a condition affecting red cell turnover.
  • Coefficient of variation (CV): a measure of glucose variability. High variability — even if the average looks acceptable — is associated with worse outcomes and more hypoglycemia risk.

In many cases, a 14-day AGP tells us more about what is actually happening than a single A1C drawn every three months. We have moved most of our diabetes conversations toward TIR as the primary target.

What CGM cannot do

A CGM reads glucose in the interstitial fluid — the fluid between your cells — not directly in the blood. There is a physiologic lag of about 5-10 minutes between blood glucose and interstitial glucose. In rapidly changing situations — a fast-acting insulin peak, vigorous exercise — the CGM may run slightly behind. This is why, during a hypoglycemia treatment, you confirm with a fingerstick before making a big decision if your CGM reading and your symptoms disagree.

CGM does not make dosing decisions for you. Having data is different from knowing how to act on it. We spend real time on this in our visits.

Sensor accuracy can also drift slightly in the final days of a sensor's life, and compression artifacts — lying directly on the sensor overnight — can cause brief false readings. Knowing these limits helps you interpret what you see with appropriate confidence.

How insurance authorization works

We handle it. Our office submits the CGM prior authorization to your insurance, including whatever supporting documentation is required. For most plans, approval takes a few days to two weeks. We will let you know what we hear. If a plan denies coverage initially, we appeal — and most appeals succeed when the clinical documentation is thorough, which ours is.

What to expect when you start

When your CGM arrives, your first step is pairing the sensor with the app on your phone. Each system has a short warmup period — typically one to two hours — during which readings are not yet stable. Some patients notice their first-day readings look a little off; this is normal as the sensor equilibrates to your interstitial fluid. Day two onward is typically accurate and reliable.

All three apps support sharing — you can add a partner, parent, caregiver, or your care team as a follower who sees your glucose in real time. We encourage patients who live alone, have significant hypoglycemia history, or manage diabetes in a child to use this feature actively.

CGM and closed-loop pump systems

The combination of a CGM with a smart insulin pump creates what is called a hybrid closed-loop system. The pump reads the CGM continuously and adjusts basal insulin delivery automatically — raising or lowering it based on where glucose is and where it is trending. Current systems we support:

  • Tandem t:slim X2 with Control-IQ + Dexcom G7
  • Omnipod 5 + Dexcom G7
  • Medtronic MiniMed 780G + Guardian 4

These systems have meaningfully improved Time in Range and reduced nocturnal hypoglycemia in clinical trials and in our own patient population. If you are on insulin and not yet on a closed-loop system, it is worth a conversation at your next visit.

How we use CGM data in your visits

We download your CGM data at every diabetes visit — no separate appointment needed, no extra step. We look at your AGP together on screen. We identify patterns: the 3 AM low that keeps waking you up, the post-lunch spike that nothing seems to touch, the wide glucose swings on heavy exercise days.

TIR is our primary conversation. It is more actionable than A1C: if your TIR is 58% and our target is 70%, we can look at exactly which hours are pulling it down and make a targeted adjustment. A1C alone does not give us that granularity.

Virtual visits work very well for CGM review — you share your screen or we pull your data directly from the cloud platform. Patients who have their CGM data in front of them during the visit are much more engaged in the adjustments we discuss, and the conversations are faster and more specific.

If you are living with diabetes and not yet on a CGM, or you are on one and not sure you are getting the most out of it, let us know at your next visit. The goal is not more data for its own sake — it is fewer lows, fewer highs, less guessing, and a life that feels less dictated by your glucose meter.

Want to talk to one of our clinicians?

New and existing patients welcome. Most major commercial plans and Medicare accepted. Two Houston-area locations and virtual visits available.

Privia Medical Group
PROUD TO BE PART OF PRIVIA MEDICAL GROUP

Endocrine and Psychiatry Center is a proud member of Privia Medical Group. The best doctors in our community have joined together to form Privia Medical Group (PMG), a multi-specialty, high-performance medical group that puts patients first. Our physicians are united by the mission of providing better, more coordinated care for their patients. To learn more about Privia Medical Group and find other Privia doctors, please visit our website.